Lenvatinib Plus Everolimus Versus Cabozantinib in Metastatic Clear Cell RCC After PD-1 Inhibitio

European Urology published a clinical update in Research Highlights on 14 Jan 2026. The item focuses on Re: A Multicenter Randomized Phase II Trial of Lenvatinib plus Everolimus Versus Cabozantinib in Patients with Metastatic Clear Cell RCC that Progressed on PD-1 Immune Checkpoint Inhibition (LenCabo). Review the original article for the full source wording and details.